$39,516.39 consulting Payment -- Roche/Genentech to Dr. Timothy Rogers

Oncology Physician Timothy Rogers Receives Significant Consulting Fee from Roche/Genentech for Keytruda Services

This page provides a detailed analysis of a $39,516.39 consulting payment from Roche/Genentech to Dr. Timothy Rogers. Data is from the CMS Open Payments (Sunshine Act) database.

Payment Details

FieldValue
Amount$39,516.39
Payment Typeconsulting
Payment NatureConsulting Fee
Pharmaceutical CompanyRoche/Genentech
PhysicianDr. Timothy Rogers
NPI Number1420694384
Physician SpecialtyOncology
LocationAlbany, NY
Date of Payment2025-05-18
Related Drug/DeviceKeytruda
Conflict AssessmentHigh -- Significant

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Roche/Genentech made a $39.5K consulting payment to Timothy Rogers, a Oncology specialist in Albany, NY. The payment was associated with Keytruda. Timothy Rogers received a substantial consulting fee of $39,516.39 from Roche/Genentech. The payment was for consulting services related to Keytruda, an oncology drug. This payment occurred on May 18, 2025, and was processed in Albany, NY.

Patient Guidance: What This Payment Means for You

If you are a patient, understand that your doctor may receive payments for consulting or other services from pharmaceutical companies, which is disclosed through programs like CMS Open Payments. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

This consulting fee of $39,516.39 for oncology services is on the higher end compared to typical consulting payments, which can vary widely based on the scope and duration of services.

Regulatory Context: Sunshine Act Requirements

This payment falls under the Sunshine Act provisions of the Affordable Care Act, requiring disclosure of financial relationships between drug manufacturers and physicians.

Related Topics

This payment is related to the following healthcare transparency topics:

Understanding consulting Payments

Consulting payments are made when pharmaceutical companies hire physicians as advisors or consultants. This can include serving on advisory boards, providing expert medical opinions on drug development or marketing strategies, and reviewing clinical data. Consulting is one of the most common forms of pharmaceutical payment to physicians and can range from a few hundred dollars for a brief consultation to tens of thousands of dollars for ongoing advisory relationships.

Frequently Asked Questions About This Payment

What was this $39.5K payment for?

This was a consulting payment of $39.5K from Roche/Genentech to Timothy Rogers, categorized as "Consulting Fee". It was associated with Keytruda. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Timothy Rogers accept pharmaceutical money?

Yes, Timothy Rogers received this $39.5K payment from Roche/Genentech. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Timothy Rogers's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this consulting payment?

A consulting payment of $39.5K may reflect legitimate advisory services the physician provides. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Oncology?

To compare this payment against Oncology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Oncology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Timothy Rogers's relationship with Roche/Genentech?

The payment amount is notably high for a single consulting engagement. This $39.5K consulting payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Oncology?

The payment nature is explicitly 'Consulting Fee', indicating a service-for-payment arrangement.

What should patients do after learning about this payment?

If you are a patient, understand that your doctor may receive payments for consulting or other services from pharmaceutical companies, which is disclosed through programs like CMS Open Payments.

What else should I know about this consulting payment?

The drug associated with the payment, Keytruda, is a prominent oncology treatment.

Related Reports

Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.